guest ::
| Home > Publications database > Low sun exposure acts synergistically with high EBNA-1 antibody levels in MS etiology. > print |
| Home > Publications database > Low sun exposure acts synergistically with high EBNA-1 antibody levels in MS etiology. > print |
| 001 | 170464 | ||
| 005 | 20240229133714.0 | ||
| 024 | 7 | _ | |a 10.1111/ene.15082 |2 doi |
| 024 | 7 | _ | |a pmid:34435414 |2 pmid |
| 024 | 7 | _ | |a 1351-5101 |2 ISSN |
| 024 | 7 | _ | |a 1468-1331 |2 ISSN |
| 024 | 7 | _ | |a 1471-0552 |2 ISSN |
| 024 | 7 | _ | |a altmetric:112423430 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-01957 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Hedström, Anna Karin |0 0000-0002-6612-4749 |b 0 |
| 245 | _ | _ | |a Low sun exposure acts synergistically with high EBNA-1 antibody levels in MS etiology. |
| 260 | _ | _ | |a Oxford [u.a.] |c 2021 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1642423234_11680 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Dec;28(12):4146-4152 |
| 520 | _ | _ | |a Among multiple sclerosis (MS) patients, an association has been observed between low levels of vitamin D and high Epstein-Barr nuclear antigen 1 (EBNA-1) antibody levels. However, whether sun exposure/vitamin D moderates the role of Epstein-Barr virus infection in MS etiology is unclear. We aimed to investigate potential synergistic effects between low sun exposure and elevated EBNA-1 antibody levels regarding MS risk.We used a population-based case-control study involving 2017 incident cases of MS and 2443 matched controls. We used logistic regression models to calculate odds ratios of MS with 95% confidence intervals (CI) in subjects with different sun exposure habits and EBNA-1 status. Potential interaction on the additive scale was evaluated by calculating the attributable proportion due to interaction (AP).Low sun exposure acted synergistically with high EBNA-1 antibody levels (AP 0.2, 95% CI 0.03-0.3) in its association to increased MS risk. The interaction was present regardless of HLA-DRB1*15:01 status.Low sun exposure may either directly, or indirectly by affecting vitamin D levels, synergistically reinforce pathogenic mechanisms, such as aspects of the adaptive immune response, related to MS risk conveyed by EBV infection. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 700 | 1 | _ | |a Huang, Jesse |b 1 |
| 700 | 1 | _ | |a Brenner, Nicole |0 P:(DE-He78)b1326dc42cbbc5f92b10fe5f254f0bc2 |b 2 |u dkfz |
| 700 | 1 | _ | |a Butt, Julia |0 P:(DE-He78)31d7c3e829be03400641f80b821ef728 |b 3 |u dkfz |
| 700 | 1 | _ | |a Kockum, Ingrid |b 4 |
| 700 | 1 | _ | |a Waterboer, Tim |0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |b 5 |u dkfz |
| 700 | 1 | _ | |a Olsson, Tomas |b 6 |
| 700 | 1 | _ | |a Alfredsson, Lars |b 7 |
| 773 | _ | _ | |a 10.1111/ene.15082 |g p. ene.15082 |0 PERI:(DE-600)2020241-6 |n 12 |p 4146-4152 |t European journal of neurology |v 28 |y 2021 |x 1351-5101 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:170464 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)b1326dc42cbbc5f92b10fe5f254f0bc2 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)31d7c3e829be03400641f80b821ef728 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-01-27 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NEUROL : 2019 |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-27 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-27 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-01-27 |
| 920 | 1 | _ | |0 I:(DE-He78)F022-20160331 |k F022 |l Infektionen und Krebs-Epidemiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F020-20160331 |k F020 |l Infektionen und Krebs-Epidemiologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F022-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|